

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: A61M 37/00		A1	(11) International Publication Number: WO 99/34858
			(43) International Publication Date: 15 July 1999 (15.07.99)
(21) International Application Number: PCT/US99/00659		(81) Designated States: CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 12 January 1999 (12.01.99)			
(30) Priority Data: 60/071,240 12 January 1998 (12.01.98) US 60/085,304 13 May 1998 (13.05.98) US		Published <i>With international search report.</i>	
(71) Applicant: GEORGIA TECH RESEARCH CORPORATION [US/US]; Centennial Research Building, 400 Tenth Street, Atlanta, GA 30332-0415 (US).			
(72) Inventors: LIU, Jin; Unit 9, 1087 Westshire Road, Atlanta, GA 30318 (US). LEWIS, Thomas, N.; 196 Eureka Drive, Atlanta, GA 30305 (US). PRAUSNITZ, Mark, R.; 1765 Peachtree Street, No. D-4, Atlanta, GA 30309 (US).			
(74) Agents: PABST, Patrea, L. et al.; Arnall Golden & Gregory, 2800 One Atlantic Center, 1201 West Peachtree Street, Atlanta, GA 30309-3450 (US).			
(54) Title: ASSESSMENT AND CONTROL OF ACOUSTIC TISSUE EFFECTS			
(57) Abstract			
<p>A method for altering the permeability of cells, tissues or other biological barriers, to molecules to be transported into or through these materials, through the application of acoustic energy, is enhanced by applying ultrasound in combination with means for monitoring and/or implementing feedback controls. The acoustic energy is applied directly or indirectly to the cells or tissue whose permeability is to be altered, at a frequency and intensity appropriate to alter the permeability to achieve the desired effect, such as the transport of endogenous or exogenous molecules, and/or fluid for drug delivery, measurement of analyte, removal of fluid, alteration of cell or tissue viability or alteration of structure of materials such as kidney or gall bladder stones.</p>			

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	MN	Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

ASSESSMENT AND CONTROL OF ACOUSTIC TISSUE EFFECTS

Background Of The Invention

5 The present invention is in the field of controlled application of acoustic energy to tissues and cells, and more particularly to assessment and control of acoustic energy as a means of enhancing the permeability of cell and tissue for administration of chemical or biological agents.

10 Ultrasound-mediated administration of drugs, genes, and other therapeutic compounds into and across cells and tissues has shown significant potential in target drug delivery. For example, studies have shown that appropriately applied ultrasound can reversibly permeabilize viable cells so that exogenous material can enter those cells without killing them. Ultrasound-enhanced delivery to cells has been demonstrated *in vitro* by uptake of extracellular fluid (Williams, *J. Cell Sci.* 12: 875-85 (1973)); drugs (Saad and Hahn, *Ultrasound Med. Biol.* 18: 715-23 (1992)); and DNA into both cells (Fechheimer, et al., *Proc. Natl. Acad. Sci. USA* 84: 8463-67 (1987); Kim, et al., *Human Gene Ther.* 7: 1339-46 (1996); Bao, et al., *Ultrasound Med. Biol.* 23: 953-59 (1997); Wyber, et al., *Pharm. Res.* 14: 750-56 (1997)) and plant tissues (Zhang, et al., *Bio/Technology* 9: 996-97 (1991)).

15 Similarly, acoustic effects of lithotripters have been shown to permeabilize cell membranes. (Holmes, et al., *J. Urol.* 147: 733-37 (1992); Gambihler, et al., *J. Membr. Biol.* 141: 267-75 (1994)). Ultrasound also has been shown to increase transport of small drugs and proteins across skin, which is of interest for topical and systemic transdermal drug delivery (Kost and Langer, "Ultrasound-mediated transdermal drug delivery" in *Topical Drug Bioavailability, Bioequivalence, and Penetration* (Shah & Maibach (eds.)) pp. 91-104 (Plenum Press, New York 1993); Mitrugoti, et al., *Pharm. Res.* 13: 411-20 (1996); (Mitrugoti, et al., *Science* 269: 850-53 (1995); Prausnitz, "Transdermal delivery of proteins: recent advances by modification of skin's barrier properties" in *Therapeutic Protein and Peptide*

Formulation and Delivery (Shahrokh, et al., eds.) pp. 124-53 (American Chemical Society, Washington, DC 1997)).

Ultrasound has been a well established diagnostic and therapeutic tool in medicine for decades (Stewart and Stratmeyer, eds., *An Overview of*

- 5 *Ultrasound: Theory, Measurement, Medical Applications, and Biological Effects* (FDA 82-8190) (U.S. Department of Health and Human Services, Rockville, MD 1983); Suslick, ed., *Ultrasound: Its Chemical, Physical, and Biological Effects* (VCH, Deerfield Beach, FL 1988)). Ultrasonic imaging is widely used at high frequency and low intensity conditions, which are
- 10 believed to cause no or minimal effects on cells (Barnett, et al., *Ultrasound Med. Biol.* 20: 205-18 (1994)). Ultrasound also is used therapeutically at somewhat greater intensities to heat tissues for physical therapy and other hyperthermia treatments (*Exposure Criteria for Medical Diagnostic Ultrasound: I. Criteria Based on Thermal Mechanisms* (NCRP Report No.
- 15 113), National Council on Radiation Protection and Measurements (Bethesda, MD 1992)). Under a very different conditions (that is, a spectrum of lower frequencies and high intensity), routine lithotripsy procedures use focused acoustic energy to noninvasively shatter kidney stones so the fragments can be excreted by the body without surgery (Coleman and
- 20 Saunders, *Ultrasonics* 31: 75-89 (1993)). Kidney stone destruction by lithotripsy is believed to be mediated by cavitation. Tachibana, et al., *Cancer Lett.* 78(1-3):177-181 (1994); *Cancer Lett.* 72(3):195-199 (1993) have reported on the use of topically applied ultrasound in combination with a photosensitizer to kill tumor cells and on the combination of topically
- 25 applied ultrasound in combination with gas containing microspheres to enhance lysis of thrombi, in *Circulation* 92(5):1148-1150 (1995) and U.S. Patent No. 5,315,998 to Tachibana, et al.

Acoustic cavitation involves the creation and oscillation of gas bubbles in a liquid (Leighton, *The Acoustic Bubble* (Academic Press, London

- 30 (1994)). During the low-pressure portion of an ultrasound wave, dissolved gas and vaporized liquid can form gas bubbles. These bubbles then shrink and grow in size, oscillating in response to the subsequent high- and low-

pressure portions of the ultrasound wave, a process referred to as stable cavitation. Transient cavitation occurs at greater acoustic pressures, where bubbles violently implode after a few cycles. This implosion can have a number of effects, including transiently raising the local temperature by

5 hundreds of degrees Celsius and the local pressure by hundreds of atmospheres, emitting light by a poorly-understood phenomenon called sonoluminescence, creating short-lived free radicals, and launching a high-velocity liquid microjet. Cavitation also is believed to be responsible for ultrasonic permeabilization of cells and tissues of interest for pharmaceutical

10 applications (Wyber, et al., *Pharm. Res.* 14: 750-56 (1997); Mitragotri, et al., *Pharm. Res.* 13: 411-20 (1996); Barnett, et al., *Ultrasound Med. Biol.* 20: 205-18 (1994)). Nonetheless, the effects of ultrasound parameters on cavitation and cell membrane permeabilization are not sufficiently understood for development and optimization of acoustic techniques in, for

15 example, controlled drug delivery.

It is therefore an object of this invention to provide quantitative assessment and control of acoustic tissue effects.

It is another object of this invention to provide means for enhancing the controlled transportation of molecules into or across cell or tissue
20 barriers.

It is still another object of this invention to provide means for reversibly or irreversibly altering cell or tissue permeability, thereby regulating transport or cell or tissue properties such as viability or structure.

25

Summary Of The Invention

A method for reversibly, or irreversibly, altering the permeability of cells, tissues or other biological barriers, to molecules to be transported into or through these materials, through the application of acoustic energy, is enhanced by applying the ultrasound in combination with means for
30 monitoring and/or implementing feedback controls. The acoustic energy is applied directly or indirectly to the cells or tissue whose permeability is to be altered, at a frequency and intensity appropriate to alter the permeability

(which includes diffusivity) to achieve the desired effect, such as the transport of endogenous or exogenous molecules and/or fluid, for drug delivery, measurement of analyte, removal of fluid, alteration of cell or tissue viability or alteration of structure of materials such as kidney or gall bladder stones.

5 In the preferred embodiment, the method includes measuring the strength of the acoustic field applied to the cell or tissue at the applied frequency or other frequencies, and using the acoustic measurement to modify continued or subsequent application of acoustic energy to the cell or 10 tissue. In another preferred embodiment, the method further includes simultaneously, previously, or subsequently exposing the cell or tissue to the chemical or biological agent to be transported into or across the cell or tissue. In another preferred application, the method includes removing biological 15 fluid or molecules from the cells or tissue simultaneously, previously or subsequently to the application of acoustic energy and, optionally, assaying the biological fluid or molecules.

In a preferred embodiment, the acoustic energy is applied at a frequency between about 1 kHz and 20 MHz, and at a peak positive pressure up to 100 atmospheres. The acoustic energy can be applied directly to the 20 tissue or cells where the effect is desired. Alternatively, the acoustic energy can be applied at a site at a distance from the transducer, under conditions designed to result in a desired effect at the distant site. Ultrasound can be applied using non-invasive means (for example, by transdermal application), minimally invasive means (for example, using a catheter), or during surgery 25 or other invasive procedures. the acoustic energy can be applied alone, or in combination with therapeutic or diagnostic agents.

The method can be used in a variety of applications, including drug delivery, including gene therapy, administration of vaccines, and administration of targeted therapeutic or diagnostic agents, detection and/or 30 quantitation of analyte, and destruction of tissues such as cancers, fatty tissue or materials such as kidney or gall bladder stones.

Brief Description of The Drawings

Figures 1a and 1b are graphs of incident ultrasonic pressure (1a) and subharmonic pressure (1b) versus percent membrane permeabilization of a suspension of bovine red blood cells exposed to continuous ultrasound for 10 sec. at 24 kHz.

Figure 2 is a graph of ultrasound frequency versus pressure, which illustrates a representative acoustic spectrum measured during an ultrasound exposure at $f = 24$ kHz, which caused extensive cavitation.

Figure 3 is a graph of ultrasound exposure time versus percent membrane permeabilization for red blood cells exposed to continuous ultrasound at 24 kHz for different amounts of time at incident pressures of 0.89 atm. (♦), 2.7 atm. (■), and 8.9 atm. (▲).

Figure 4 is a graph of length of time of an ultrasound pulse versus percent membrane permeabilization of cells for pulses applied at a duty cycle of 10% at incident pressures of 0.89 atm. (♦), 2.7 atm. (■), and 8.9 atm. (▲).

Figure 5 is a graph of ultrasound duty cycle (%) versus percent membrane permeabilization at an incident pressure of 2.7 atm., for a total "on" time of 10 sec. at a pulse length of 0.1 sec. (♦) or 1 sec. (■).

Figure 6 is a graph of the acoustic parameter $\tau \cdot P_{02}$ versus percent membrane permeabilization, using the data from Figures 1-5.

Figure 7 is a graph showing average uptake of calcein molecules per exposed cell (o) and fraction of viable cells (■) relative to unexposed control, each as a function of peak incident pressure for 20 pulses at 0.1 sec. and 10% duty cycle.

Figure 8 is a graph showing average uptake of calcein molecules per cell as a function of time at which calcein was added to the cell suspension after exposure.

Detailed Description Of The Disclosure

Acoustic energy can be used to cause chemical or biological agents to be transported into and/or across biological barriers, for example, in cells or tissue. Characterizing the dependence of cell membrane permeabilization on

acoustic energy conditions is, however, essential to rationally designing acoustic energy protocols for pharmaceutical and other applications.

Accordingly, methods are provided herein to use the quantitative dependence of cell membrane permeabilization on various acoustic parameters to

- 5 enhance the transport of chemical or biological agents to be transported into and/or across biological barriers in cells or tissue, for example, to enhance delivery of drugs to cells in a specific tissue or to increase uptake of compounds which cross cell membranes poorly.

I. Acoustic Energy

- 10 As used herein, the term "acoustic energy" means any form of pressure wave, whether audible or inaudible. The frequency of the acoustic energy can be a single frequency or a combination of frequencies. The range of useful frequencies preferably is between about 1 Hz and 100 MHz, and more preferably is between about 15 kHz and 2 MHz. The waveform of the
- 15 acoustic energy can be of any shape, including a sinewave or a combination of sinewaves. The pressure of the acoustic energy can be up to a few hundred atmospheres, and preferably is applied at a peak positive pressure of up to 100 atmospheres. The optimal pressure is a function of acoustic frequency and other parameters described below. The acoustic energy can
- 20 be applied continuously or intermittently.

Acoustic energy can be used to enhance transport by a number of different mechanisms, which broadly fall into two classes. In the first class, acoustic energy directly or indirectly (e.g., via cavitation) provides a driving force for transport. In the second class, acoustic energy increases the

- 25 permeability of the biological barrier, either reversibly, partially reversibly, or irreversibly. These two mechanisms can be used independently or in combination. In the preferred embodiment, both mechanisms are used simultaneously.

In the first class, where acoustic energy directly or indirectly provides

- 30 a driving force for transport, both cavitational and non-cavitational mechanisms can be involved. Under appropriate low frequency, high pressure conditions, acoustic energy can cause cavitation, which is the

creation of gas cavities, or bubbles, which oscillate stably in the acoustic field and/or collapse, as can be seen during transient or inertial cavitation. The appropriate conditions will depend on the temperature, gas content, acoustic conditions, viscosity and the other properties of the system and 5 acoustic field. Cavitational and non-cavitational acoustic energy also can provide convective or hydrodynamic driving forces for transport, including acoustic streaming, microstreaming, and local, high-velocity jets caused by transient cavitation. Also, chemical and other changes caused by acoustic energy can alter the local environment, thereby changing local chemical 10 potentials, which can alter the chemical potential driving force for net transport by diffusion.

In the second class, where acoustic energy increases the permeability of the biological barrier, either reversibly, partially reversibly, or irreversibly, both cavitational and non-cavitational mechanisms can be 15 involved. For example, increased permeability can be achieved by heating, thereby increasing diffusivity of the molecules. Increased permeability can also be achieved by altering physical structures within biological barriers, such as re-organizing the structure of lipid bilayers, intercellular junctions, and extracellular matrix. These physical effects can be caused by one or 20 more factors, including bulk heating, cavitation, acoustic streaming, microstreaming, high-velocity jets, mechanical interactions, local heating by cavitation, local pressure increases by cavitation, and chemical effects due to creation of free radicals, or stimulation of other chemical reactions.

Preselected Conditions

25 Acoustic enhancement can be used to alter transport (typically by altering permeability to the molecules to be transported to the material through which they are to pass) or structural integrity of biological materials. The parameters can be selected prior to application, based on previous studies or empirical results. In a preferred method, however, feedback is 30 obtained so that the acoustic enhancement is modified after the initial application as needed to optimize results as treatment progresses.

Acoustic Measurement Feedback

Feedback can involve measurement of one or more variables.

- Variables include subharmonic pressure, acoustic parameters, temperature, amount or rate of transport of molecules, extent of cavitation, and degree of
- 5 permeabilization.

As described in Example 1 below, membrane permeabilization is mediated by cavitation, so that subharmonic pressure can be used as a noninvasive way to determine the degree of permeabilization resulting from exposure to acoustic energy. In addition, permeabilization caused by

- 10 ultrasound should be well predicted by the acoustic parameter $\tau.P_{f2}$, which characterizes the total cavitation exposure by accounting for both the strength of the $f/2$ cavitation signal and the time over which it acts.

In a preferred embodiment, the method of enhancing transport of chemical or biological agents across or into a biological barrier includes the

- 15 following steps:

- (a) applying acoustic energy to the biological barrier, for example, the cells or tissue, at one or more frequencies;
- (b) measuring the strength of the acoustic field applied to the cells or tissue at the applied frequency or other frequencies; and
- 20 (c) using the acoustic measurement obtained in step (b) to modify continued or subsequent application of acoustic energy to the cells or tissue.

For example, in a preferred embodiment, a device applies ultrasound to a tissue and the $f/2$ signal is measured to assess the degree to which the tissue was permeabilized. This information can be used to estimate the

- 25 amount of drug delivered. Measurement of the $f/2$ signal provides a method for real-time feedback so that the ultrasound exposure based on pre-programmed or user-selected drug delivery profiles can be optimized. The technology required for both generating acoustic energy and "listening" to $f/2$ signals is known in the art, relatively inexpensive when mass produced,
- 30 and is readily miniaturizable.

II. Chemical or Biological Agents

The methods described herein can be used to enhance transport of

essentially any endogenous or exogenous chemical or biological agent for therapeutic, diagnostic, or prophylactic purposes into or across biological barriers. Useful agents include peptides, proteins, sugars, polysaccharides, nucleotides, polynucleotide molecules, and other synthetic organic or

5 inorganic compounds. Representative proteins and peptides include hormones such as insulin, growth factors, and vaccines. Representative polynucleic acid molecules include antisense, aptamers, ribozymes, and genes, plasmids, and viral vectors. Representative synthetic organic or inorganic drugs include anti-inflammatories, antivirals, antifungals,

10 antibiotics and local anesthetics. As used herein, the agents can be molecules or aggregates or other multi-molecular structures, including for example, virus particles or cells, liposomes or other lipid vesicles or emulsions, or particles including nano or microspheres or capsules. For direct application, the drug will typically be administered in an appropriate

15 pharmaceutically acceptable carrier having an acoustic impedance similar to water, such as an aqueous gel, ointment, lotion, or suspension. Alternatively, a transdermal patch can be used as a carrier.

A variety of analytes are routinely measured in the body fluids such as blood, interstitial fluid, lymph, intracellular fluid or cerebral spinal fluid.

20 Examples of typical analytes that can be measured include blood sugar (glucose), cholesterol, bilirubin, creatinine, vitamin K or other clotting factors, uric acid, carcinoembryonic antigen or other tumor antigens, and various reproductive hormones such as those associated with ovulation or pregnancy. Other analytes that can be measured include alcohol and drugs.

25 **III. Applications**

The methods described herein can be used to enhance transport of agents into or across a variety of biological barriers. Representative barriers include mammalian and non-mammalian tissues, including skin, tumor, muscle, lung, brain, heart, blood vessel, bone, cartilage, and internal organs.

30 The tissue or cell can be a part of a living organism, obtained from a living organism, or intended to become part of a living organism, for example, for use in tissue regeneration or tissue engineering, in the form of tissue or

dissociated cells. Other representative biological barriers include externally accessible barriers, such as skin, the eye (cornea, conjunctiva, sclera), and the mucosa of the nose, mouth, rectum and vagina, as well as internal barriers, such as the gastrointestinal tract and pulmonary mucosa, blood and lymphatic vessel walls (including the blood-brain barrier), internal organs, tumors, and bones. The barrier can be in the form of intercellular junctions, extracellular matrices, or cell membranes for introduction of material into or out of the interior of a cell or cells. In one preferred embodiment, the biological barrier is human skin.

10 As used herein, the phrase "biological barrier" encompasses cell membranes, tissue, tissue membranes, intracellular membranes, and biological materials such as kidney stones. It is understood that the technology can be applied directly or indirectly to these materials.

15 The methods of enhancing transport can be performed with acoustic energy parameters that are preselected and/or that are adjusted based on acoustic measurement feedback.

Acoustic enhancement can precede, occur simultaneously, or follow treatment with other agents which may be used in combination with the ultrasound to affect transport. For example, chemical enhancers that increase 20 solubility of the materials to be transported, permeability enhancers, or even other driving forces such as mechanical or physical forces (vacuum, pressure, electrical forces) may be used with the ultrasound.

Acoustic enhancement which is administered to enhance transport out 25 of cells or tissues, for example, for measurement of analyte, is administered in an amount which is effective, alone or in combination with other transport enhancers, to extract analyte for detection or quantitation. Acoustic enhancement which is administered to enhance transport of fluid out of tissue or cells is administered in an amount which is effective, alone or in combination with other transport enhancers, to extract fluid, for example, as 30 required to reduce swelling or shrink tissue for easier extraction using other methods or to facilitate breakdown of structural integrity.

Acoustic enhancement which is administered to degrade structural integrity or kill cells is administered in an amount effective to dissociate cells or tissue or other material such as a kidney or gall bladder stone (usually formed of calcium and/or lipid materials) or to irreversibly alter the cell 5 permeability so that the cells become unviable.

Acoustic enhancement which is administered to enhance transport is administered directly or indirectly as required to alter the rate or extent of transport. Enhancement may be measured by an increase in transport, for example, using a marker such as blood levels following transdermal delivery, 10 or through an end result, for example, following introduction of genes into tissue, by expression of the product encoded by the genes.

The transport methods described herein can be used to alter transport as part of a variety of procedures. Acoustic energy can be focused on the target tissue, using an invasive, minimally-invasive, or non-invasive method, 15 to increase transport locally without significantly affecting other tissues. In a preferred embodiment, acoustic energy is applied non-invasively using one or more transducers to focus energy onto the body surface or at a site deeper in the body. In another preferred embodiment, a minimally-invasive method is used, in which, for example, one or more transducers are attached to a 20 laproscopic device for the treatment of tissue accessible from the gastrointestinal tract in, for example, the treatment of colon cancer, or to a catheter for the treatment of tissue accessible from the vasculature in, for example, the treatment of atherosclerosis or restinosis. An invasive approach can be used to treat any tissue. For example, the acoustic energy can be 25 applied in conjunction with another invasive procedure, such as surgery.

In a preferred embodiment, transdermal delivery of a drug, such as insulin, is enhanced by the use of acoustic energy to cause compounds to be transported into and/or across the skin. In another preferred embodiment, a biological material, such as glucose, is transported out of the body 30 through/from the skin using a method facilitated by acoustic energy.

In a similar preferred embodiment, a drug is delivered from outside the body to its interior, or a molecule from inside the body to the exterior.

across barriers other than skin, such as the epithelia of the eye, nose, mouth, rectum, or vagina, using a method facilitated by acoustic energy.

In another preferred embodiment, acoustic energy is used to enhance targeted drug delivery by selectively increasing transport of a drug into a

5 target tissue, such as the brain or a tumor. Some tissues, such as tumors, are particularly resistant to transport. Accordingly, acoustic energy can significantly enhance delivery of drug to those tissues.

Other compounds, particularly larger macromolecules, are especially difficult to drive into cells or tissue of any type. The transport of these

10 compounds also can be enhanced by application of acoustic energy. For example, in gene therapy, a target tissue could be treated with acoustic energy to facilitate delivery of DNA into cells.

The compositions and methods of preparation and use thereof described herein are further described by the following non-limiting

15 examples.

Example 1: Exposure of Bovine Red Blood Cells to Ultrasound

The dependence of cell membrane permeabilization on ultrasound parameters was determined and the acoustic signals which correlate with

20 observed membrane permeabilization were identified.

Experimental Methods

Bovine red blood cells were exposed to ultrasound at 24 kHz over a range of controlled conditions. The degree of membrane permeabilization was measured by release of hemoglobin and was determined as a function of

25 ultrasound parameters and measured acoustic signals.

Sample preparation

Freshly drawn bovine blood with Alsevers anticoagulant (Rockland, Gilbertsville, PA) was stored at 4 °C for up to 10 days. Red blood cells were collected by centrifugation (GS-15R, Beckman Instruments, Palo Alto, CA;

30 400 g, 10 min., 4 °C); washed three times with phosphate-buffered saline (PBS; pH 7.4; Sigma, St. Louis, MO); and then suspended in PBS at a red blood cell concentration of 10% by volume. The cell suspension was stored

on ice and then gently mixed on a nutator (Innovative Medical Systems, Ivyland, PA) immediately before use in an experiment.

The cell suspension was added to a sample tube, which was prepared by cutting a 15 ml polypropylene centrifuge tube (VWR, Suwanee, GA) at 5 the 4 ml line. After the sample tube was filled with 4 ml of the cell suspension, a rubber stopper (VWR) was carefully inserted into the tube to the 3 ml line, thereby spilling out about 1 ml of the suspension. This procedure was used so that the tube could be sealed without entrapping air bubbles. A hydrophone (Baylor School of Medicine, Houston, TX) also was 10 inserted through a small hole in the center of the rubber stopper and positioned at the center of the sample volume.

Exposure to ultrasound

The ultrasound exposure chamber consisted of a cylindrical piezoelectric transducer (lead zirconate titanate, 5 cm OD, 4.5 cm ID, 2.5 cm 15 length; Channel Industries, Santa Barbara, CA) sandwiched between two 10 cm lengths of 1.5 inch Schedule 40 poly(vinyl chloride) (PVC) pipe. The bottom of the chamber was sealed on a clear polycarbonate base (LEXAN™, General Electric, Mt. Vernon, IN). The chamber was filled with water which was filtered/deionized (Type III; U.S. Filter, Roswell, GA) and degassed 20 using a vacuum chamber (Nalgene, Rochester, NY; pump: 2107VA20A, Thomas, Sheboygan, WI).

The sample tube was placed in the water bath within the ultrasound exposure chamber, positioned at the axial and radial center of the transducer, and exposed to low-frequency (24 kHz) ultrasound at room temperature 25 (22±2 °C). A function generator (DS345, Stanford Research Systems, Sunnyvale, CA) was programmed to provide a sinewave of selected voltage, duty cycle, burst length, and total exposure time. The output was fed to an amplifier (Macro-tech 2400, Crown, Elkhart, IN), the signal of which went through a matching transformer (MT-56R, Krohn-Hite, Avon, MA) to drive 30 the transducer.

Measurement of ultrasound pressure

To monitor the ultrasound exposure, the voltage applied to the

transducer was measured with an oscilloscope (54603B, Hewlett Packard, Santa Clara, CA). This voltage was used to estimate the incident ultrasound pressure, as described below. In addition, the signal from the hydrophone in the sample tube was fed to the oscilloscope and a spectrum analyzer (SR760,

5 Stanford Research Systems), which was used to determine the amplitude of different acoustic signals shown in Figure 2 and Table 1. Higher harmonics of f (e.g., $2f=48$ kHz) are seen in Figure 2, due to cavitation and apparatus resonance. Cavitation also generates other signals, including the subharmonic ($f/2=12$ kHz) and its ultraharmonics (e.g., $3f/2=36$ kHz) and an 10 elevated broadband "noise" level (e.g., $b1, b2$). The acoustic spectrum measured during exposure of cells to ultrasound provided information about cavitation and its effects on membrane permeability, as described below.

The strength of ultrasound is reported as its incident pressure. The incident pressure is defined as the pressure level that would exist in the 15 absence of cavitation, which is primarily at the driving frequency (i.e., 24 kHz). The incident pressure is important because one of the effects of cavitation is to shift acoustic energy to frequencies other than the driving frequency, as shown in Figure 2. Incident pressure is the most useful means to characterize ultrasound, because it is independent of apparatus geometry 20 and represents the total relevant acoustic input. For propagating wave fields created by a planar transducer at high frequency, ultrasound strength is often reported as an intensity (e.g., in units W/cm^2). For ultrasonic irradiation of a surface such as skin with a planar transducer, this approach seems appropriate (Kost and Langer, "Ultrasound-mediated transdermal drug 25 delivery" in *Topical Drug Bioavailability, Bioequivalence, and Penetration* (Shah & Maibach, eds.) pp. 91-104 (Plenum Press, New York 1993)). In this experiment, however, a radially-symmetric standing wave-like field is generated because of the cylindrical geometry of the transducer and because of the use of low frequency ultrasound with a wavelength comparable to the 30 apparatus diameter, which field makes acoustic intensity extremely difficult to determine. Alternatively, the reported pressure can be directly measured with a hydrophone at the driving frequency. While this approach is useful at

low acoustic levels where the measured pressure has the same value as the incident pressure, at higher intensities where cavitation occurs, acoustic energy is shifted to a spectrum of other frequencies, as shown in Figure 2. Thus, the pressure measured at the driving frequency accounts for only a portion of the ultrasound exposure applied to the cells.

The peak incident pressure generated within the exposure chamber was estimated by measuring the acoustic pressure at subcavitation levels and linearly extrapolating to higher drive levels (Matula, et al., *J. Acoust. Soc. Am.* **101**: 1994-2002 (1997)). At supra-cavitation levels, the incident pressure continues to increase as a linear function of the voltage, whereas the measured pressure levels off and may decrease due to cavitation. A linear fit of the data was therefore generated only at low pressure (i.e., less than 2.0 atm. for degassed water) for the pressure as a function of transducer voltage:

$$P = 0.0089 \cdot V \quad (r^2=0.99) \quad (1)$$

where peak positive pressure (P) has units of atmospheres and peak-to-peak voltage (V) has units of volts. This equation was extrapolated to higher voltages and pressures and was used to convert measured transducer voltages to the incident pressures described in these examples.

Measurement of ultrasound power and heating

Bulk heating caused by ultrasound was measured and determined to be less than 1 °C for all exposures. Using an iron/constantant thermocouple (Model SA1-J thermocouple; Model DP 460 display; Omega Engineering, Stamford, CT) inserted into the water bath, which was mixed using a stir bar and magnetic stirrer (VWR), the temperature was determined to rise at 0.17 °C/min. during continuous exposure to ultrasound at 2.2 atm. and at 0.73 °C/min. at 4.5 atm incident pressure.

Although incident pressure, rather than power, is used to characterize the strength of ultrasound, it should be helpful to know the power of ultrasound exposures used here for comparison with other studies.

Assuming that all acoustic energy from the transducer was eventually converted into heat and that heat loss from the apparatus to the surroundings was negligible, the measured heating rates described above can be used to

determine the power output of the transducer with the equation

$$W = m_{\text{water}} C_{P\text{water}} dT/dt \quad (2)$$

where W is power, m_{water} is the mass of water in the water bath (0.3 kg), $C_{P\text{water}}$ is the heat capacity of water (4.18 J/g°C), and dT/dt is the change of temperature with respect to time (e.g., 0.17 °C/min. at 2.2 atm.). For example, this equation yields 3.4 W at 2.2 atm and 15.1 W at 4.5 atm. using the heating rates given provided above. This type of calorimetric method is commonly used to estimate ultrasonic power (Kimura, et al., *Ultrasonics Sonochem.* 3: S157-S161 (1996)).

10 A second method to determine the power of ultrasound exposures was to measure the electrical power supplied to the transducer. The values determined by the two methods should be equal if there is complete conversion of electrical power to acoustic power by the transducer (i.e., 100% efficiency). The voltage across the transducer was measured directly

15 with an oscilloscope (model 2430A, Tektronics, Beaverton, OR) and the current was measured using a current transformer (Model 2100, Pearson Electronics, Palo Alto, CA) and fed to the oscilloscope. The average power was calculated as the average of the product of the current and voltage signals and yielded the following relationship

$$20 W = 0.00010 \cdot V^2 \quad (r^2 = 1.00) \quad (3)$$

where power (W) has units of watts and peak-to-peak voltage (V) has units of volts. Combination of Equations 1 and 3 yields the following equation which relates power to incident pressure for the experimental apparatus used herein:

$$25 W = 1.3 \cdot P^2 \quad (4)$$

where power (W) has units of watts and incident pressure (P) has units of atmospheres. This equation indicates the power is 6.3 W at 2.2 atm and 26 W at 4.5 atm, which are considerably higher than the values determined using Equation 2. This overprediction is expected, since Equation 4 assumes

30 100% efficient conversion of electrical energy by the transducer into acoustic energy. In contrast, Equation 2 yields an underprediction, since perfect

insulation of the apparatus is assumed. Thus, Equations 2 and 4 provide upper and lower bounds for the acoustic energy.

Post-exposure analysis

After exposure to ultrasound, samples were removed from the sample tube and spun down, as described above. The supernatant contained free hemoglobin released from permeabilized cells, while the pellet contained intact cells. The supernatant was collected and the absorbance of hemoglobin in the supernatant was determined at 575 nm using a spectrophotometer (DU-64, Beckman Instruments). As a positive control, the absorbance was also determined for a sample in which all cells were lysed by suspension in deionized water. The ratio of these absorbances yielded the percent hemoglobin released, expressed as percent membrane permeabilization in the Figures described herein.

Results

To develop a rational approach to designing protocols for ultrasound-mediated cell membrane permeabilization, the degree of permeabilization of bovine red blood cells exposed to low-frequency (24 kHz) ultrasound was measured as a function of incident ultrasound pressure, total exposure time, pulse length, and duty cycle. In addition, the amount of permeabilization was correlated with measurable acoustic signals, which is of interest to noninvasive monitoring of ultrasound's bioeffects and elucidation of mechanisms. The degree of permeabilization was measured by release of hemoglobin from erythrocytes.

Figure 1a shows that permeabilization increased with increasing incident pressure (f=24 kHz), a measure of the total ultrasound exposure which cannot be measured directly in the presence of cavitation. Permeabilization exhibited an almost linear dependence for pressures greater than ~0.5 atm, which is consistent with previous studies which show that bioeffects increase with ultrasound pressure or intensity (Stewart & Stratmeyer, eds., *An Overview of Ultrasound: Theory, Measurement, Medical Applications, and Biological Effects* (FDA 82-8190), U.S. Department of Health and Human Services (Rockville, MD 1983); Suslick,

ed., *Ultrasound: Its Chemical, Physical, and Biological Effects* (VCH, Deerfield Beach, FL 1988); Barnett, et al., *Ultrasound Med. Biol.* 20: 205-18 (1994); *Exposure Criteria for Medical Diagnostic Ultrasound: I. Criteria Based on Thermal Mechanisms (NCRP Report No. 113)* (Bethesda, MD 1992)). Figure 1b shows that permeabilization increased with increasing subharmonic pressure ($f/2=12$ kHz), a measure of cavitation which can be measured directly. These figures indicate that membrane permeabilization is mediated by cavitation and that measurement of subharmonic pressure may be a noninvasive way to determine the degree of permeabilization (and thereby the amount of drug delivery) resulting from ultrasound exposure.

Figure 2 shows a representative spectrum of acoustic signals associated with an ultrasound exposure which causes extensive cavitation. A strong signal is seen at the driving frequency, f (i.e., 24 kHz), which is the frequency at which the transducer resonates. Due to cavitation and other effects, there are also strong signals at integer multiples of the driving frequency (e.g., $2f$, $3f$, and $4f$) and at the subharmonic frequency, $f/2$, and its ultraharmonics (e.g., $3f/2$, $5f/2$, and $7f/2$). The broadband noise pressure between these peaks (e.g., b_1 and b_2) also is elevated.

It was assessed whether cell membrane permeabilization correlates with any of these features of the acoustic spectrum, as summarized in Table 1. The correlation was strongest for P_{02} (i.e., the pressure at $f/2$) and its ultraharmonics (set 2). Figure 1b shows this relationship graphically. Permeabilization also correlated with average measurements of broadband noise pressure between the peaks (set 3). The driving frequency itself and its higher harmonics (set 1) showed the weakest correlation. Previous studies have correlated cell damage with P_{02} (Jeffers, et al., *J. Acoust. Soc. Am.* 97: 669-76 (1995)) and 20 f (Everbach, et al., *Ultrasound Med. Biol.* 23: 619-24 (1997)). Mechanistic interpretation of these results is provided below. These correlations may provide a useful means for noninvasively measuring cell permeabilization by ultrasound.

The effect of total exposure time of a single continuous ultrasound exposure is shown in Figure 3. In each case, permeabilization increased with

exposure time above a threshold of approximately 100 msec. Below approximately 100 msec, ultrasound had little effect on the cells. For longer exposures, membrane permeabilization increased as a strong function of exposure time. This is in qualitative agreement with previous studies 5 conducted under somewhat different conditions, which also show that membrane disruption increases with exposure time above a threshold (Kober, et al., *J. Acoust. Soc. Am.* **86**: 6-7 (1989); Brayman, et al., *Ultrasound Med. Biol.* **22**: 927-38 (1996)).

In Figure 4, cells were exposed to ultrasound using pulses of different 10 length, but the cumulative "on" time for each set of pulses was kept constant at 10 sec by varying the total number of pulses. Pulses were applied at a duty cycle of 10% and at three different incident pressures: (♦) 0.89 atm., (■) 2.7 atm., and (▲) 8.9 atm. Permeabilization showed a weak dependence 15 on pulse length, with a small, but statistically significant, peak at 3 msec. for both 2.7 atm. and 8.9 atm. ($p < 0.05$, by Student's T-test, relative to average permeabilization at pulse lengths ≥ 0.1 sec). For each pressure tested, the degree of membrane permeabilization varied little as a function of pulse length. There was, however, a small statistically-significant peak in 20 permeabilization at 3 msec. A possible physical explanation for this peak is discussed below.

For pulsed ultrasound, the effect of duty cycle (defined as the fraction of time that the ultrasound is "on" during pulsed application) is shown in Figure 5. Under the conditions investigated, duty cycle had no significant effect on the degree of membrane permeabilization.

25 Figure 1b shows that P_{02} is predictive of the degree of membrane permeabilization from exposures of different incident pressure, all having the same pulse length, exposure time, and duty cycle. To generalize the approach and consider exposures of different pulse lengths, exposure times, duty cycles and incident pressures, membrane permeabilization was 30 correlated with the total exposure time (τ), which is equal to the product of pulse length and the number of pulses applied, multiplied by the strength of the $f2$ signal (P_{02}). As shown in Figure 6, this parameter ($\tau \cdot P_{02}$) correlated

well with membrane permeabilization, showing a threshold value at approximately 0.01 (i.e., $\log(\tau \cdot P_{D2}) = -2$). Below this threshold little permeabilization occurred, and above it permeabilization increased sharply. Because Figure 6 includes all of the data collected in this study and because

5 the parameter $\tau \cdot P_{D2}$ correlates well with the whole data set, it appears that measurement of this single parameter can provide a simple, non-invasive, and broadly-applicable method for determining membrane permeabilization caused by any acoustic energy exposure.

The parameter $\tau \cdot P_{D2}$ was chosen because it characterizes the total

10 cavitation exposure by accounting for both the strength of the $f/2$ cavitation signal (P_{D2}) and the time over which it acts (τ). The good correlation between permeabilization and $\tau \cdot P_{D2}$ is significant because measurement of this single parameter can provide a simple, non-invasive method for determining membrane permeabilization caused by any ultrasound exposure.

15 These studies showed that permeabilization increased with incident ultrasound pressure, increased with total exposure time above a threshold of approximately 100 msec, showed a weak dependence on pulse length with a small maximum at 3 msec, and did not depend on duty cycle under the conditions examined. Using measured acoustic spectra, it was found that red

20 blood cell membrane permeabilization correlated best with the pressure measured at half the driving frequency ($f/2 = 12$ kHz) and its ultraharmonics, less strongly with the broadband noise pressure measured between peaks, and least strongly with pressure measured at the driving frequency and its higher harmonics. Permeabilization caused by ultrasound applied at any set

25 of conditions tested in this study could be well predicted by the parameter $\tau \cdot P_{D2}$, which characterizes the total cavitation exposure.

Discussion

Effect of ultrasound parameters

This study shows that permeabilization increases as a strong function

30 of incident pressure (Figure 1) and total exposure time (Figure 3), which indicates that selection of appropriate pressure and duration of ultrasound exposure is important to achieve permeabilization at a desired level. The

existence of a threshold near 100 msec of total exposure time (Figure 3) also constrains possible protocols. In contrast, the observation that permeabilization depends only weakly on pulse length (Figure 4) and duty cycle (Figure 5) is useful, since it permits greater flexibility in designing 5 ultrasound protocols.

The effects of different ultrasound parameters summarized above can be explained in terms of cavitation, the mechanism by which membranes are believed to be disrupted (Barnett, et al., *Ultrasound Med. Biol.* 20: 205-18 (1994); Leighton, *The Acoustic Bubble* (Academic Press, London 1994)). It 10 is well established that at greater acoustic pressure more cavitation bubbles with greater energy are created (Leighton, *The Acoustic Bubble* (1994)). Similarly, longer total exposure times also yield more cavitation bubbles. This increased cavitation should result in more extensive membrane 15 permeabilization, as seen in Figures 1 and 3. The minimum exposure time of 100 msec shown in Figure 3 could result from the "warm-up" time it takes for bubbles to nucleate, grow, and possibly collapse over many ultrasound cycles (Margulies, *Sov. Phys. Acoust.* 22: 145-47 (1976)).

The maximum permeabilization observed for 3 msec pulses in Figure 4 could be explained by two competing effects involving a mechanism 20 proposed previously (Ciaravino, et al., *Ultrasound Med. Biol.* 7: 159-66 (1981)). Increasing pulse length is advantageous for cavitation because there is more time during each pulse for bubbles to nucleate, grow and collapse. However, it is believed that as pulse length increases so does the time 25 between pulses at constant duty cycle, which means that as the interpulse delay increases, bubbles formed during the previous pulse have time to dissolve back into solution. This mechanism is disadvantageous because it leaves fewer nucleation bubbles available to grow and collapse during the next pulse, which results in less cavitation.

Correlation with measured acoustic signals

30 Ultrasound causes cavitation which in turn causes effects on cells. Therefore the most useful predictor of ultrasound's effects on cells should be a measure of cavitation. Membrane permeabilization was correlated with

measured acoustic signals which are known to be associated with cavitation.

A good correlation was found for the pressure measured at half the driving frequency ($f/2 = 12$ kHz) and its ultraharmonics (Figure 1b, set 2 of Table 1).

In addition, permeabilization caused by ultrasound applied at any set of

5 conditions tested in this study could be well predicted by the parameter $\tau.P_{02}$, which characterizes the total cavitation exposure by accounting for both the strength of the $f/2$ cavitation signal and the time over which it acts.

Correlation of acoustic signals with membrane permeabilization also provides mechanistic insight. The best correlation was found for the signal

10 at $f/2$ and its ultraharmonics (set 2 of Table 1, Figure 1b). This suggests that permeabilization was mediated by cavitation. Onset of the $f/2$ signals is thought to occur with the onset of cavitation (Leighton, *The Acoustic Bubble* (1994)). As the cavitation activity increases, the $f/2$ signals also generally increase, but a quantitative relationship between amount of cavitation and
15 P_{02} has not been established. Cavitation bubbles are thought to give off a signal at $f/2$ because of a prolonged expansion phase and delayed collapse which can occur during cavitation (Leighton, *The Acoustic Bubble* (1994)). Measurement of $f/2$ signals at the exact frequency of interest (e.g., 12 kHz; set 2a) yielded a somewhat better correlation with permeabilization than
20 measurement of the signal over the width of the peak (e.g., 11-13 kHz; set 2b).

A reasonable correlation also was established for measurements of broadband signals, or the signals between f , $f/2$, and higher harmonics (set 3 of Table 1), which also supports a permeabilization mechanism involving

25 cavitation, especially transient cavitation. Upon bubble collapse during transient cavitation, "noise" over a broad spectrum of frequencies is given off, which raises peak and broadband signals alike (Leighton, *The Acoustic Bubble* (1994)). Since both $f/2$ and broadband signals showed correlation, it appears that both stable and transient cavitation play a role in membrane
30 permeabilization.

Finally, signals at f and its higher harmonics showed the poorest correlation (set 1 in Table 1). This was expected since these signals are

related to the non-cavitational driving frequency (f) and resonance of the experimental apparatus (higher harmonics), in addition to stable and transient cavitation. The signal f and its higher harmonics are not expected to be good indicators, since it reflects a mixture of effects.

5 **Conclusion**

This study provides a quantitative guide to designing ultrasound protocols useful for drug delivery. The acoustic measurements support the hypothesis that ultrasonic cavitation is the mechanism by which membranes are permeabilized. They also indicate that measurable acoustic signals can

10 provide noninvasive real-time feedback about membrane permeabilization and drug delivery.

Using red blood cells as a model system, it was shown that membrane permeabilization increases with incident ultrasound pressure, increases with total exposure time above a threshold of 100 msec, shows a

15 weak dependence on pulse length with a small maximum at 3 msec, and does not depend on duty cycle under the conditions examined. In addition, the degree of permeabilization was shown to correlate with measurable acoustic signals (e.g., P_{02} , $\tau.P_{02}$), which supports the belief that permeabilization is mediated by cavitation and may provide a method for noninvasive, real-time

20 feedback for an intelligent delivery system.

Table 1: Empirical Correlation of Membrane Permeabilization with Measured Acoustic Signals

	Frequency (kHz) ^a	Correlated Equation ^b	r^2 ^c
Set 1a	24 (f) ^d	$M = 19.7 \ln(P) + 30.6$	0.58
	48 (2f)	$M = 12.4 \ln(P) + 43.2$	0.66
	72 (3f)	$M = 11.8 \ln(P) + 49.2$	0.58
	96 (4f)	$M = 11.4 \ln(P) + 53.6$	0.45
Set 1b	23-25 (f)	$M = 19.7 \ln(P) + 65.0$	0.64
	47-49 (2f)	$M = 12.7 \ln(P) + 64.8$	0.70
	71-73 (3f)	$M = 12.3 \ln(P) + 68.9$	0.66
	95-97 (4f)	$M = 11.7 \ln(P) + 69.4$	0.60
Set 2a	12 (f/2)	$M = 9.4 \ln(P) + 73.0$	0.84
	36 (3f/2)	$M = 8.5 \ln(P) + 64.7$	0.85
	60 (5f/2)	$M = 8.7 \ln(P) + 64.4$	0.85
	84 (7f/2)	$M = 9.6 \ln(P) + 69.6$	0.85
Set 2b	11-13 (f/2)	$M = 10.1 \ln(P) + 79.8$	0.81
	35-37 (3f/2)	$M = 9.0 \ln(P) + 70.8$	0.81
	59-61 (5f/2)	$M = 9.3 \ln(P) + 70.3$	0.82
	83-85 (7f/2)	$M = 9.8 \ln(P) + 73.1$	0.82
Set 3	13-23 (b1)	$M = 10.2 \ln(P) + 82.3$	0.75
	25-35 (b2)	$M = 10.5 \ln(P) + 82.9$	0.75
	37-47 (b3)	$M = 10.2 \ln(P) + 80.6$	0.79
	49-59 (b4)	$M = 10.6 \ln(P) + 78.2$	0.78
	61-71 (b5)	$M = 10.3 \ln(P) + 78.2$	0.79
	73-83 (b6)	$M = 10.6 \ln(P) + 79.7$	0.79
	85-95 (b7)	$M = 10.2 \ln(P) + 77.0$	0.78

5 ^a Based on spectral information such as that shown in Figure 2, membrane permeabilization was correlated with the pressure (or the average pressure when a range of frequencies is given) measured at the frequency (or range of frequencies) indicated.

10 ^b The equation which resulted from a log-linear fit of membrane permeabilization (M) and measured pressure (P) is shown. There is no mechanistic basis for the log-linear functionality; visual inspection suggested it was the most appropriate fit of the data. The units of permeabilization are percent hemoglobin released and the units of pressure are atm.

^c The r^2 correlation coefficient is shown for each fit of the data.

^d The text in parentheses refers to which harmonic of the driving frequency (f=24 kHz) the indicated frequencies correspond and "b" indicates a broadband noise measurement.

**Example 2: Ultrasound-Mediated Disruption of
Prostate Tumor Cell Membranes**

Introduction

The effects of ultrasound exposure on size, lifetime, and permeability
5 of membrane disruptions in living cells were investigated quantitatively. It
was found that ultrasound disruptions were a few nanometers in size, have a
lifetime of approximately one minute, and induce extensive molecular
uptake.

Methods

10 Prostate tumor cells (DU-145) were suspended in RPMI-1640
medium with 10% fetal bovine serum at 5×10^5 cells/ml. For each
experimental condition, a 3 ml polypropylene tube was filled with the cell
suspension at room temperature (22 ± 2 °C) and the top of the tube was
closed without entrapping any air bubbles. The cells were exposed to
15 ultrasound at 24 kHz in a chamber that consisted of a cylindrical
piezoelectric transducer sandwiched between two PVC pipes and filled with
deionized and degassed water at room temperature. Pressure, pulse length,
duty cycle, and the total exposure time of ultrasound exposure were
controlled. Acoustic spectra during exposure were collected using a
20 hydrophone placed in the exposure chamber. Calcein, a green-fluorescent
membrane-impermeant marker, dissolved in saline, was added to the
suspensions either before or at various times after exposure at a final
concentration of 10 μ M. Other fluorescent markers, with different sizes,
were also used to determine membrane permeability. The cells were kept at
25 room temperature for 15 minutes after exposure, and then placed on ice until
they were centrifuged and resuspended in phosphate-buffered saline with 0.1
mg/ml of propidium iodide (a red-fluorescence viability stain). Cell-by-cell
fluorescence was measured using flow cytometry, and 6 μ m
green-fluorescence microspheres were added to each sample at a constant
30 concentration to provide an internal volumetric standard for determining
concentrations of viable cells.

Results and Discussion

To better understand how cells are permeabilized by ultrasound, potential mechanisms of membrane disruptions were tested. First, it was observed that cells were permeabilized only in presence of extensive

5 cavitation, as indicated by characteristic changes in measured acoustic spectra (i.e., strong subharmonic and ultraharmonic peaks and broad band noise). Other effects of ultrasound, such as bulk heating and mixing were ruled out as potential mechanisms, since control experiments of heating (up to 2 °C, the maximum temperature rise in these experiments) and mixing had

10 negligible effects on cells. Also, cavitation-induced free radicals probably are not responsible, because membrane permeabilization was observed in the presence of free radical scavengers (e.g., 50 µM cysteamine). Therefore, microscale hydrodynamic effects of cavitation probably are the main factor in disrupting cell membranes.

15 The effects of ultrasound exposure parameters on cell viability and membrane permeabilization (as measured by uptake of calcein added to the cell suspension before exposure) were determined to identify conditions that selectively permeabilize cells without killing them. As peak incident pressure increased, average cellular calcein uptake increased above a

20 threshold and reached a plateau at 20-25% of external calcein concentration (Figure 7). However, the fraction of viable cells (relative to an unexposed suspension) decreased continuously with increasing pressure (Figure 7). Uptake increased with total exposure time and reached a plateau at 5 sec. (for P=5.3 atm. and 10 ms pulses at 10% duty cycle), while cell viability

25 decreased continuously. Average uptake showed a small maximum at 10-33 ms and a sharp decline at less than 3 ms, with changes in pulse length from 0.3 ms to 1.0 s. Applied duty cycle (from 0.5% to 80%) did not significantly affect uptake. Fraction of viable cells decreased as uptake increased for most conditions, and was approximately 25% for maximum uptake under optimal

30 conditions.

Membrane disruptions were found to be large enough to allow uptake of bovine serum albumen (radius, r approximately 3.5 nm). Average uptake

of BSA molecules per exposed cell was about 60% less than that of calcein ($r \approx 0.7$ nm), for the same external concentration (10 μM) and same exposure conditions as given in Figure 7 (at $P=8.0$ atm.).

To determine lifetimes of the membrane disruptions, calcein was added to cell suspensions at different times after ultrasound exposure. As shown in Figure 8, average uptake of calcein decreased exponentially with time at which calcein was added to a sample (≥ 15 s after exposure). The data at three incident pressures, 5.3 atm. (o), 7.1 atm. (■), and 8.0 atm. (▲), were fitted with exponential functions, and shown in Figure 8. The respective time decay constants, τ , at these pressures were 78 sec., 66 sec, and 56 sec., respectively. One can see that the time decay constant, τ , decreased and the initial uptake increased with increasing incident pressure. Average uptake was about 50% less when calcein was added 15 sec. after exposure compared to when it was added before exposure for the examined pressures. However, significant uptake occurred for up to two minutes after exposure.

We claim:

1. A method for altering permeability, cell viability or structural integrity of biological materials comprising
 - (a) administering acoustic energy to the biological materials at one or more frequencies;
 - (b) measuring the effect of the acoustic energy or a property of the acoustic energy at the time of or subsequent to the initial application of the acoustic energy; and
 - (c) using the measurement obtained in step (b) to modify continued or subsequent application of acoustic energy to the biological materials.
2. The method of claim 1 wherein the property of the acoustic energy being measured in step b is one or more properties selected from the group consisting of pressure at one or more frequencies, energy input at one or more frequencies, and length of time the acoustic energy is administered.
3. The method of claim 1 wherein the acoustic energy is effective to alter permeability of the biological materials to a chemical or biological agent selected from the group consisting of peptides, proteins, sugars, polysaccharides, nucleotides, polynucleotide molecules, synthetic organic compounds, synthetic inorganic compounds, and combinations and aggregates thereof.
4. The method of claim 3 wherein the agent is in a form selected from the group consisting of cells or virus particles, nano or microparticles, liposomes or other lipid vesicles or emulsions.
5. The method of claim 3 wherein the chemical or biological agent is delivered to cells or tissue.
6. The method of claim 3 wherein the chemical or biological agent is detected or quantitated, further comprising
 - removing biological fluid or molecules simultaneously, previously, or subsequently to the application of acoustic energy; and
 - assaying the biological fluid or molecules to detect or quantitate the chemical or biological agents.

7. The method of claim 1 wherein the acoustic energy is administered to kill cells.
8. The method of claim 1 wherein the biological materials are made more permeable by the exposure to acoustic energy.
9. The method of claim 8 wherein the increased permeability is partially or completely reversible.
10. The method of claim 1 wherein the biological materials are biological membranes.
11. The method of claim 1 wherein the biological material is skin.
12. The method of claim 1 wherein the acoustic energy is applied to biological materials in an amount effective to disaggregate or dissociate the materials.
13. The method of claim 1 wherein the biological materials are blood vessels.
14. The method of claim 1 wherein the acoustic energy is applied at a frequency between 1 kHz and 10 MHz.
15. The method of claim 1 wherein the acoustic energy is ultrasound.
16. The method of claim 1 wherein the acoustic energy is applied at a peak positive pressure of up to 100 atmospheres.
17. The method of claim 1 wherein the application of acoustic energy causes cavitation within or on the surface of the biological materials.
18. The method of claim 1 further comprising administering an agent to enhance transport within or permeability of the biological materials.
19. The method of claim 1 wherein the acoustic energy or pressure is measured at one or more frequencies other than the frequency or frequencies at which the acoustic energy is applied.
20. The method of claim 1 wherein the acoustic energy or pressure is measured at a frequency or frequencies corresponding to integer multiples of one-half or one-fourth of the frequency applied.

21. The method of claim 1 wherein the acoustic energy is measured at one or more frequencies which do not correspond to peaks in the acoustic spectrum and are taken from the broadband signal of the spectrum.
22. The method of claim 19 wherein the acoustic energy measurement is analyzed using a mathematical algorithm, such as Fourier Transform or the Fast Fourier Transform.
23. The method of claim 1 wherein the application of the acoustic energy is modified by changing an acoustic parameter selected from the group consisting of pressure, energy, frequency, pulse length, total exposure time, duty cycle, and combinations thereof.
24. The method of claim 1 wherein the application of the acoustic energy is modified by changing a non-acoustic parameter selected from the group consisting of temperature, fluid gas content, administration rate of molecules to be transported, sample collection rate, device position, and combinations thereof.
25. The method of claim 1 wherein the application of the acoustic energy input is modified by interrupting the application.
26. A device for use in the method of any of claims 1-25.
27. A method for altering transport of chemical or biological agents into or through biological materials or cell viability in a human or other animal using acoustic energy, wherein the biological materials or cells are at a site distant from the site of application of the acoustic energy, comprising:
 - administering acoustic energy at one or more frequencies by applying a transducer to a first site on the human or other animal;
 - wherein the acoustic energy alters transport or cell viability at a second site in the human or other animal distant from the first site.
28. The method of claim 27 wherein the first site is skin or a mucosal membrane and the second site is at an internal organ, tissue or vessel.
29. The method of claim 27 wherein the cells are tumor cells.

30. The method of claim 27 wherein the acoustic energy alters transport of molecules selected from the group consisting of therapeutic, prophylactic and diagnostic agents.

31. The method of claim 27 wherein the transducer is directly applied to a tissue other than the biological materials where transport or cell viability is to be altered.




FIG. 1A




FIG. 1B

2/5




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6

5/5




FIG. 7




FIG. 8

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/00659

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61M 37/00

US CL : 600/309; 601/2; 604/20, 22, 49, 290

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 601/2; 600/309; 604/20,22,49,290

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used).

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,656,016 A (OGDEN) 12 August 1997, entire document.	1-5, 7-18, 23-25
X	US 5,636,632 A (BOMMANNAN et al) 10 June 1997, entire document.	1-13, 15-18, 23-25
X	US 5,445,611 A (EPPSTEIN et al) 29 August 1995 , entire document.	27-31

 Further documents are listed in the continuation of Box C. See patent family annex.

Special categories of cited documents:	
A	document defining the general state of the art which is not considered to be of particular relevance
B	earlier document published on or after the international filing date
L	document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
O	document referring to an oral disclosure, use, exhibition or other means
P	document published prior to the international filing date but later than the priority date claimed
"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"A"	document member of the same patent family

Date of the actual completion of the international search
18 MARCH 1999Date of mailing of the international search report
15 APR 1999Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231
Facsimile No. (703) 305-3230Authorized Officer
RUTH S. SMITH
Telephone No. (703) 308-3063

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/00659

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: 26 because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
The claim fails to set forth any structure of the device.

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.